Reportedly providing enhanced imaging of structural heart disease, the minimally invasive X11 4t Mini 3D TEE ultrasound transducer facilitates use of the technology in smaller pediatric patients as well as high-risk ICU patients.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the X11 4t Mini 3D TEE transducer, a device that may broaden the use of transesophageal echocardiography (TEE) to patients in intensive care units (ICUs) and smaller pediatric patients.
The enhanced imaging capability with three-dimensional TEE in assessing structural heart disease can help save lives, according to Philips, the manufacturer of the X11 4t Mini 3D TEE transducer. The company added that the technology can also be beneficial for minimally invasive heart surgery cases.
Noting the device’s pill-shaped design and a 35 percent smaller size than other TEE transducers, Philips said the X11 4t Mini 3D TEE transducer enables clinicians to utilize the technology for ICU patients as well as smaller pediatric patients.
“In many of our smallest patients undergoing complex intracardiac procedures like valve repairs, 3D TEE will give us a new and much needed perioperative tool,” noted Brian Soriano, M.D., FASE, a pediatric cardiologist at Seattle Children’s Hospital.
“For example, the X11-4t (Mini 3D TEE transducer) can help us visualize atrioventricular valves en face. In many cases, this is a view that is difficult to achieve with traditional 2D TEE. 3D TEE will also be a more effective tool to communicate with the surgeons and will enable us to give good ‘surgeon views’ of intracardiac structures.”
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.